tbuckley/cabot-search huggingface dataset:
A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro
Authors: Sheng Chen, Feifei Gu, Kang Li, Kai Zhang, Yangyang Liu, Jinyan Liang, Wei Gao, Gang Wu, Li Liu
Journal: Journal of Hematology & Oncology (2017)

Adoptive transfer of cytotoxic T lymphocytes (CTLs) holds promises to cure cancer. However, this treatment is hindered by lacking a robust way to specifically expand out CTLs. Here, we developed a hybrid of B lymphoblastic cell line and T lymphoblastic cell line (T2 cells) as a substitute of dendritic cells, together with irradiated autologous peripheral blood mononuclear cell (PBMC) as feeder cells and rhIL-2, to activate and expand Her-2/neu-specific CD8+ T cells from human epidermal growth factor receptor 2 (Her-2/neu) and human leukocyte antigen (HLA)-A2 double positive advanced breast cancer patients in vitro. These Her-2/neu-loaded T2 cells reproducibly activated and expanded out Her-2/neu-specific CD8+ T cells to 107 in 8 weeks. Furthermore, these Her-2/neu-specific CD8+ T cells had good sensitivity of recognition and killing Her-2/neu-overexpressed breast cancer cell line SK.BR.3. This technique gives us another insight on how to rapidly obtain sufficient CTLs for adoptive cancer immunotherapy.
The Administration of Day 11 Methotrexate (MTX) for GVHD Prophylaxis Improves Outcomes for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplantation (PBSC) : An Individual Patient Data Meta-Analysis (IPDMA) from the Stem Cell Trialists Collaborative Group.
Authors: William I. Bensinger
Journal: Blood (2004)
Evaluation of falls in older adults in a comprehensive cancer center: How are we doing?
Authors: Emily Jean Guerard, Allison Mary Deal, Grant Richard Williams, Trevor Augustus Jolly, Hyman Bernard Muss
Journal: Journal of Clinical Oncology (2014)

9545 Background: Falls are a major cause of morbidity and mortality in older adults (> 65 years old) with as many as one in three reporting a fall in the previous year. Twenty percent of falls lead to serious injuries resulting in declines in function and increased likelihood of institutionalized care. Screening for falls is quick and simple and should be included in the clinical evaluation of an older adult by all clinicians since proven interventions to decrease falls can lead to improvements in function, treatment tolerability, and overall quality of life. The aim of this study is to evaluate medical oncologists’ ability to recognize and intervene on falls in older cancer patients. Methods: As of October 2013, the Carolina Senior Registry had a total of 528 cancer patients greater than 65 years old seen at UNC who were queried about falls as part of a brief geriatric assessment (GA) [Hurria et. al. J. Clin Oncol 2011]. The history and physical and/or clinic notes completed by a medical oncologist within six months after completion of the GA were retrospectively reviewed for the following: documentation of falls, gait assessment, referral to either geriatrics or physical and/or occupational therapy, and measurement of a 25-hydroxy vitamin D level. Results: 125 (24%) of the 528 UNC cancer patients in the registry had at least one fall in the previous 6 months. Of these 125 patients, 54% had one fall and 47% had two or more falls. Seventy of these charts were reviewed and the results are shown in the Table. Conclusions: In an academic comprehensive cancer center, older adults who fall were not adequately evaluated by medical oncologists. Our estimates indicate that no more than 10% of patients who experience falls have appropriate medical record documentation or referrals. Practical time-sensitive methods for identification and management of falls are needed. We plan to test a point of service tool to improve medical oncologists’ awareness of falls and expedite referrals for effective interventions. Supported in part by the Breast Cancer Research Foundation, New York, NY. Outcomes N=70 (100%) 95% CI Falls documented 2 (3%) 0-10% Gait assessment 13 (19%) 10-30% Referrals 2 (3%) 0-10% Vitamin D level 13 (19%) 10-30%
Impact of Hematopoietic Cell Transplantation with Total Body Irradiation on the Health Status of Childhood Leukemia Survivors: A Report from the Childhood Cancer Survivor Study (CCSS).
Authors: K. Scott Baker, Wendy Leisenring, Robert Hayashi, Amanda Termuhlen, Ann Mertens, Sarah Donaldson, John Whitton, Marilyn Stovall, Leslie Robison, Charles Sklar
Journal: Blood (2005)
Primary Central Nervous System Lymphoma Treatment Outcomes-a Decade's Experience from a Single Centre in Riyadh, Saudi Arabia
Authors: Imran K Tailor, Taimoor Hussain, Wafa Shakweer, Ibraheem H Motabi, Ghulam Murtaza, Syed Ziauddin A. Zaidi, Nawal F Shehry, Mubarak S. AlGhamdi, Yasser Bayoumi, Samer Mudaibigh
Journal: Blood (2016)
Characterization of heart rate (HR) changes during crizotinib treatment: A retrospective analysis of 1,053 ALK+ NSCLC patients.
Authors: Sai-Hong Ignatius Ou, Yiyun Tang, Anna Polli, Keith D. Wilner, Patrick Schnell
Journal: Journal of Clinical Oncology (2014)

8106 Background: Decreases in HR have been described in patients receiving crizotinib. We performed a large retrospective analysis of HR changes during crizotinib therapy. Methods: Subjects with ALK+ NSCLC enrolled in PROFILE 1005 and in the crizotinib arm of PROFILE 1007 were included in this analysis. Sinus bradycardia (SB) was defined as HR <60 beats per min (bpm). Magnitude and timing of HR changes and changes in systolic (SBP) and diastolic blood pressure (DBP) were assessed. Subjects with no baseline or no on-treatment HR were excluded. Potential risk factors including age, gender, and race were investigated by chi-square tests of association. Results: 1,053 subjects were analyzed. For all subjects, median duration of therapy was 24.4 wk (range 0.6–108.3), meanHRdecrease on treatment was 25 bpm (standard deviation [SD] 15.8), and median time to within 5 bpm of the lowest HR recorded was 6.1 wk (range 0.7–60.3).441 (41.9%) subjects had ≥1 lowest HR that qualified as SB, of which 5.9% had a lowest HR of <45 bpm, 18.8% had a lowest HR of 45–49 bpm, and 75.3% had a lowest HR of 50–59 bpm. Mean decrease in HR was 30 bpm (SD 13.8) for the 441 SB subjects with a median time to within 5 bpm of the lowest HR of 9.3 wk (range 1.7–60.3). Of 4900 paired BP and HR recordings from 542 subjects without relevant concomitant medication, a ≥40-mmHg decrease in SBP was observed in 0.3% (0.6%) of recordings in the presence (absence) of SB, and a ≥30-mmHg decrease in DBP was observed in 0.6% (0.7%). Of 963 paired BP and HR recordings from 117 subjects who had concomitant beta blockers (BBs), a ≥40-mmHg decrease in SBP was observed in 0.9% (1.7%) of recordings in the presence (absence) of SB, while a ≥30-mmHg decrease in DBP was observed in 1.8% (2.0%). Only 66 instances of SB were recorded as AEs: n=55 for grade 1, n=9 for grade 2, and n=2 for grade 3. Significant associations between age (P=0.003) as well as ethnicity (P=0.039) with SB were noted in this study, with higher proportions of subjects ≥65 y as well as non-Asians developing SB. Conclusions: HR decreaseis common with crizotinib. Age ≥65 y and non-Asian ethnicity may predispose to the development of SB with crizotinib. Concomitant use of BBs may accentuate BP decrease with crizotinib.
Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.
Authors: Hideto Matsui, Margareth Ozelo, Carol Hegadorn, Andrea Labelle, Erin Burnett, Angie Tuttle, Brian Brown, Luigi Naldini, Christine Hough, David Lillicrap
Journal: Blood (2007)
Abstract P1-11-10: Clinical applications of near infra-red imaging system for localization of non-palpable breast lesions in breast conserving surgery
Authors: S-Y Jung, S Lee, SK Kim
Journal: Cancer Research (2017)

Abstract Backgrounds: Localization of non-palpable breast lesions is important for obtaining tumor-free resection margin and achieving better cosmetic outcome. Near infra-red (NIR) imaging system has been introduced for localization in breast surgery. This study aimed to evaluate the feasibility of localization using NIR imaging system in breast conserving surgery (BCS) (ClinicalTrials.gov identifier: NCT 02172989/ NCT02473159). Materials and Methods: Between June 2014 and October 2015, 20 women with benign neoplasm and 5 patients with early breast cancer were enrolled and underwent BCS using NIR imaging system. Before surgery, Indocyanine green was injected intratumoraly in benign lesions and peritumoraly for resection margins in early breast cancer. Their pathologic results for resection volume and re-excision rate were compared with those of the patients with 99 benign neoplasm and 203 early breast cancer who were treated with BCS by conventional method, respectively. Results: In the patients with benign lesions, the mean size in sonography was 1.48±0.98 cm in NIR group and 1.32±0.96cm in conventional group (P=0.4). There was no difference of pathologic lesion size and excised specimen size between these groups (1.57±0.78 cm vs 1.42±0.80 cm in pathologic lesion size; P=0.63, 4.28± 0.48 cm vs 4.15±1.37 cm in specimen size; P=0.73). In NIR group, the ratio of excised specimen/lesion was lesser than that of conventional group (3.19 ±1.40 vs 4.31±3.86; P=0.008). In addition, positive margin rate after BCS in early breast cancer patients was 0% in NIG group and 19.7% in conventional group. And re-excision rate was 0% and 4.4%, respectively. Conclusions: This study showed that localization using NIR image system could be a feasible method to obtain safe resection margins and optimum resection volumes in patients undergoing breast conserving surgery. This research was supported by National Cancer Center Grant NCC-1410202-1 &amp; NCC-1410202-2 by the National Cancer Center, Republic of Korea. Citation Format: Jung S-Y, Lee S, Kim SK. Clinical applications of near infra-red imaging system for localization of non-palpable breast lesions in breast conserving surgery [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-11-10.
Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?
Authors: David J Fisher, James R Carpenter, Tim P Morris, Suzanne C Freeman, Jayne F Tierney
Journal: BMJ (2017)

Identifying which individuals benefit most from particular treatments or other interventions underpins so-called personalised or stratified medicine. However, single trials are typically underpowered for exploring whether participant characteristics, such as age or disease severity, determine an individual's response to treatment. A meta-analysis of multiple trials, particularly one where individual participant data (IPD) are available, provides greater power to investigate interactions between participant characteristics (covariates) and treatment effects. We use a published IPD meta-analysis to illustrate three broad approaches used for testing such interactions. Based on another systematic review of recently published IPD meta-analyses, we also show that all three approaches can be applied to aggregate data as well as IPD. We also summarise which methods of analysing and presenting interactions are in current use, and describe their advantages and disadvantages. We recommend that testing for interactions using within-trials information alone (the deft approach) becomes standard practice, alongside graphical presentation that directly visualises this.
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Authors: Sherif Abdelaziz Ibrahim, Ramy Gadalla, Eslam A. El-Ghonaimy, Omnia Samir, Hossam Taha Mohamed, Hebatallah Hassan, Burkhard Greve, Mohamed El-Shinawi, Mona Mostafa Mohamed, Martin Götte
Journal: Molecular Cancer (2017)

Inflammatory breast cancer (IBC), a particularly aggressive form of breast cancer, is characterized by cancer stem cell (CSC) phenotype. Due to a lack of targeted therapies, the identification of molecular markers of IBC is of major importance. The heparan sulfate proteoglycan Syndecan-1 acts as a coreceptor for growth factors and chemokines, modulating inflammation, tumor progression, and cancer stemness, thus it may emerge as a molecular marker for IBC.We characterized expression of Syndecan-1 and the CSC marker CD44, Notch-1 & -3 and EGFR in carcinoma tissues of triple negative IBC (n = 13) and non-IBC (n = 17) patients using qPCR and immunohistochemistry. Impact of siRNA-mediated Syndecan-1 knockdown on the CSC phenotype of the human triple negative IBC cell line SUM-149 and HER-2-overexpressing non-IBC SKBR3 cells employing qPCR, flow cytometry, Western blotting, secretome profiling and Notch pharmacological inhibition experiments. Data were statistically analyzed using Student's t-test/Mann-Whitney U-test or one-way ANOVA followed by Tukey's multiple comparison tests.Our data indicate upregulation and a significant positive correlation of Syndecan-1 with CD44 protein, and Notch-1 & -3 and EGFR mRNA in IBC vs non-IBC. ALDH1 activity and the CD44(+)CD24(-/low) subset as readout of a CSC phenotype were reduced upon Syndecan-1 knockdown. Functionally, Syndecan-1 silencing significantly reduced 3D spheroid and colony formation. Intriguingly, qPCR results indicate downregulation of the IL-6, IL-8, CCL20, gp130 and EGFR mRNA upon Syndecan-1 suppression in both cell lines. Moreover, Syndecan-1 silencing significantly downregulated Notch-1, -3, -4 and Hey-1 in SUM-149 cells, and downregulated only Notch-3 and Gli-1 mRNA in SKBR3 cells. Secretome profiling unveiled reduced IL-6, IL-8, GRO-alpha and GRO a/b/g cytokines in conditioned media of Syndecan-1 knockdown SUM-149 cells compared to controls. The constitutively activated STAT3 and NFκB, and expression of gp130, Notch-1 & -2, and EGFR proteins were suppressed upon Syndecan-1 ablation. Mechanistically, gamma-secretase inhibition experiments suggested that Syndecan-1 may regulate the expression of IL-6, IL-8, gp130, Hey-1, EGFR and p-Akt via Notch signaling.Syndecan-1 acts as a novel tissue biomarker and a modulator of CSC phenotype of triple negative IBC via the IL-6/STAT3, Notch and EGFR signaling pathways, thus emerging as a promising therapeutic target for IBC.
Gene Expression Profiling with Principal Component Analysis Depicts the Biological Continuum From Essential Thrombocythemia Over Polycythemia Vera to Myelofibrosis
Authors: Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Riley, Morten Krogh Jensen, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch
Journal: Blood (2010)
Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) - a Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)
Authors: Liat Vidal, Anat Gafter-Gvili, Martin H. Dreyling, Michael Unterhalt, Pia Raanani, Michele Ghielmini, Ronit Gurion
Journal: Blood (2016)
ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase
Authors: Delphine Rea, Gianantonio Rosti, Nicholas CP Cross, Andrzej Hellmann, Dietger Niederwieser, Ester Pungolino, Franca Falzetti, Patrizia Pregno, Ester Maria Orlandi, Antonio Almeida, Arpad Illes, Miguel Sagues, Jens Haenig, Sharon Supekar, Seema Shah, Giuseppe Saglio, Juan Luis Steegmann, Michele Baccarani
Journal: Blood (2016)
Dll4 Blockade Modifies the Bone Marrow Vascular Niche and Improves Donor Bone Marrow Cells for Bone Marrow Transplant
Authors: Leonor Remédio, Tânia Carvalho, Francisco Caiado, Ana Bastos Carvalho, António Duarte, Hideo Yagita, Sérgio Dias
Journal: Blood (2011)
International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) – Upshaw-Schulman Syndrome
Authors: Magnus Mansouri Taleghani, Yoshihiro Fujimura, James N. George, Ingrid Hrachovinova, Paul Knoebl, Bernhard Lämmle, Petter Quist-Paulsen, Reinhard Schneppenheim, Johanna A. Kremer Hovinga Strebel
Journal: Blood (2012)
Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients
Authors: Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Aleksander Skotnicki, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Liliya Sivcheva, Jiri Mayer, Barbara Grohmann-Izay, Hans Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian
Journal: Blood (2016)
Abstract IA17: Application of PDX models to pancreas cancer research
Authors: Manuel Hidalgo
Journal: Clinical Cancer Research (2016)

Abstract Pancreatic cancer remains one of the most deadly cancers. Very few therapeutics advanced have been achieved in this disease. Over the last few years, several studies have started to elucidate the molecular biology of PDAC including the genomic landscape of the disease, the importance of the stroma and the immunesuppressive environment characteristic of PDAC. One important development in translational research in PDAC is the availability of preclinical models of the disease. This includes genetically engineered mouse models of cancer, patient derived xenografts (aka Avatar models) and organoids. These models are becoming useful for drug screening, biomarker development and personalize medicine. Using Avatar models we identified Nab-paclitaxel as an effective agent in pancreas cancer in contrast to paclitaxel that does not result antitumor effects. We also showed that Nab-paclitaxel disrupts PDAC stroma, an observation, however, has not been confirmed by others. In addition, studies in mouse models revealed the lack of predictability of SPARC expression for clinical outcome. More recently, we have identified demcizumab and palbociclib as potentially effective agents in PDX models as the basis for their clinical development. PDX models have also de potential to be used as a platform for personalizes cancer treatment. In this regard, we are now conducting the AVATAR clinical trial in which patients with advanced cancer are randomized to receive either a conventional treatment or a treatment based on integrating genomic data with AVATAR mouse mode development. Citation Format: Manuel Hidalgo. Application of PDX models to pancreas cancer research. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA17.
Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts,
Authors: Timoleon Anguita, Alexandre Chiattone, Nelson Hamerschlak, Rima M Saliba, XiaoWen Tang, Depei Wu, Alejandro Majilis, Araci M. Sakashita, Viviane C. Chiattone, Jose C. Barros, Carlos S Chiattone, Jose Mauro Kutner, Morgani Rodrigues, Andrea Tiemi Kondo, Grace-Julia Okoroji, Claudia Mac-Donald Bley do Nascimento, Juliana Folloni Fernandes, Uday Popat, Richard E Champlin, Paolo Anderlini, Marcos De Lima, Chitra M Hosing
Journal: Blood (2011)
The JAK2-Selective Inhibitor NS-018 Preferentially Suppresses CFU-GM Colony Formation By Bone-Marrow Cells From High-Risk Myelodysplastic Syndrome Patients
Authors: Ayumi Kodama, Haruna Naito, Yohei Nakaya, Ayako Tamura, Yoshiaki Chinen, Tomohiko Taki, Junya Kuroda, Masafumi Taniwaki
Journal: Blood (2013)
Exosomal MicroRNA for Detection of Cardiac Sarcoidosis
Authors: Elliott D. Crouser, Nabeel Y. Hamzeh, Lisa A. Maier, Mark W. Julian, May Gillespie, Mohammad Rahman, David Baxter, Xiaogang Wu, S. Patrick Nana-Sinkam, Kai Wang
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Identification of a New AHI-1-Mediated-PP2A-Beta-Catenin-BCR-ABL-JAK2 Complex Modulating Resistance of CML Stem/Progenitor Cells to Tyrosine Kinase Inhibitors
Authors: Damian Lai, Xiaohu Liu, Min Chen, Katharina Rothe, Jiang Xiaoyan
Journal: Blood (2015)
Abstract P4-08-02: Integration of transcriptomic, proteomic and drug response data in triple negative breast cancer cell lines and PDX models
Authors: CE Mills, MA Hafner, PK Sorger
Journal: Cancer Research (2017)

Abstract Drug response screens on panels of cell lines aimed at identifying markers of sensitivity or resistance have been limited in their successes. Unfortunately, the recent release of many such studies has been accompanied by concerns surrounding reproducibility. Since then, several publications have addressed these concerns by pointing out sources of variability and by suggesting better experimental methods as well as more robust analytical approaches. In the presented profiling effort, we integrated the latest advances in drug response measurement and focused on data diversity and quality rather than on breadth. We selected 32 breast cancer cell lines with a strong bias towards triple negative lines as well as 4 cell lines established from relevant patient-derived xenografts. We used high content microscopy to assay the phenotypic responses of the cell lines to a panel of 34 drugs made up largely of kinase inhibitors currently in the clinic along with some standard of care chemotherapeutics. The microscopy based drug response assay allowed us to measure drug potency, and to quantify the efficacy of the drugs in terms of growth inhibition and cell death. For the same cell lines, we used RNAseq to measure basal mRNA expression levels and shotgun mass spectrometry to measure endogenous protein levels. The completeness and controlled conditions under which these data sets were collected provide confidence in their integration. The complementarity of these multi-omics data has allowed us to address questions about the landscape of, particularly triple negative, breast cancer cell lines. Such questions include: where do the patient-derived lines lay among the established cell lines? and how different are the landscapes defined by drug response phenotypes, mRNA expression, and protein levels? We used network-based algorithms to identify eigenstates of signaling pathways related to genomic events, and further explored these states in the TCGA data. At the level of drug response, we have focused on important questions related to the clinical use of kinase inhibitors. In particular, we compared various CDK inhibitors in an effort to identify markers that are informative of response potency and efficacy. We have also looked at variability of the responses of the cell lines studied to multiple PI3K inhibitors that either target specific isoforms or all isoforms. Overall the data set that has been collected is a valuable resource for understanding drug response in triple negative breast cancer, and the transcriptomic and proteomic factors that influence it. Citation Format: Mills CE, Hafner MA, Sorger PK. Integration of transcriptomic, proteomic and drug response data in triple negative breast cancer cell lines and PDX models [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-08-02.
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Authors: Kim N Chi, Celestia S Higano, Brent Blumenstein, Jean-Marc Ferrero, James Reeves, Susan Feyerabend, Gwenaelle Gravis, Axel S Merseburger, Arnulf Stenzl, Andries M Bergman, Som D Mukherjee, Pawel Zalewski, Fred Saad, Cindy Jacobs, Martin Gleave, Johann S de Bono
Journal: The Lancet Oncology (2017)